Navigation Links
Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals
Date:7/21/2011

RIDGEFIELD, Conn., July 21, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has been added to hospital formularies at 49 of the top 50 cardiology and heart surgery hospitals, as ranked by U.S. News & World Report's Best Hospitals 2011-2012, published online on July 19.  PRADAXA is approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).(1)

Atrial fibrillation (AFib), characterized by an irregular heartbeat,(2) increases the risk of stroke nearly five times.(3)  Approximately 80 percent of U.S. adults living with AFib are age 65 or older,(4) and many have other conditions, such as diabetes or hypertension, that further increase the risk of stroke.(2)  A Medicare claims database analysis showed that approximately 70 percent of NVAF patients are hospitalized each year.(5) Overall, annual hospital admissions for NVAF, as a primary or secondary diagnosis, total nearly 2.7 million or approximately seven percent of all hospital admissions in the U.S.(6)  

"At Boehringer Ingelheim, patients are our first priority and we've worked with hospitals across the country to support the addition of PRADAXA to formularies," said Wa'el Hashad, vice president, cardiovascular and metabolic disorders marketing, Boehringer Ingelheim Pharmaceuticals, Inc. "In the first seven months after approval, more than 250,000 patients were prescribed PRADAXA, suggesting this important treatment has been well received in the everyday clinical setting to reduce the risk of stroke in patients with non-valvular atrial fibrillation."

PRADAXA is now included on formularies that insure about 90 percent of covered lives in the U.S.(7)  For those patients who may not otherwise be able to afford treatment, BIPI offers patient assista
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)
2. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
3. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
4. Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
5. Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
6. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
7. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
8. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
9. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
10. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
11. Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500mg Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... -- Endo International plc (NASDAQ: ENDP ) (TSX: ENL) announced ... will present a corporate overview at the UBS Global Healthcare ... Wednesday, May 20, 2015 at 11:00 a.m. ET.  ... will be available on the Company,s website at www.endo.com ... the event. Participants should allow approximately 10 minutes prior to ...
(Date:5/6/2015)... May 06, 2015 Tenney, a Thermal ... lines of standard and custom environmental test chambers ... innovative engineering and design, robust construction, and superior performance, ... to meet all of your temperature, humidity, altitude, vibration, ... addition of the TPS Smart 1.0 Controller. The Smart ...
(Date:5/6/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. ... cancers, today announced that Linda Powers , NW Bio CEO, ... vaccine platform for solid tumor cancers and the Company,s multiple ...   , , , DATE: , , , ... , , , 12:15 PM EDT , , , ...
(Date:5/6/2015)... CA (PRWEB) May 06, 2015 ... today announced NX-Hivac, the only high vacuum AFM system ... needs for failure analysis semiconductor manufacturing. Park NX-Hivac is ... in failure analysis solutions in highly doped semiconductor processing ... required. , The high vacuum scanning spreading resistance ...
Breaking Biology Technology:The TPS 3.5” Smart 1.0 Controller Raises the Tech Standard on Environmental Test Chambers 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3
... Inc. (Sparta),the maker of TrackWise(R), and the market ... that its TrackWise solution has,been chosen by Protherics ... manufacturing and marketing of specialized products for,critical care ... handling,processes. TrackWise provides organizations with a single, ...
... Oct. 24 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... to discuss its financial results for the quarter ended,September ... on Thursday,November 1, 2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) ... management and will be,held on Thursday, November 1, 2007, ...
... Call on Thursday, October 25, 2007 at ... ... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company focused ... the treatment of life-threatening,diseases, including diabetes and cancer, today announced its ...
Cached Biology Technology:Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management 2Human Genome Sciences To Sponsor Conference Call To Discuss Third Quarter 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 6
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... to improve durability in fuel cell powered buses, including ... between electrode degradation processes and bus membrane durability. , ... stressors in the operating cycle of the bus on ... led by SFU graduate student Natalia MaCauley, are the ...
... The discovery of potential environmental and human health effects ... year has led scientists to recommend stronger government policies ... battery materials. That,s the conclusion of a new paper ... . Oladele A. Ogunseitan and colleagues point out ...
... insects and wild plants have slowed in recent years, according ... of Leeds and the Naturalis Biodiversity Centre in the Netherlands ... species in Britain, Belgium and the Netherlands between the 1950s ... with a slowdown in local and national biodiversity losses among ...
Cached Biology News:Tests lead to doubling of fuel cell life 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
Normal sheep serum collected from healthy normal sheep...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Biology Products: